Defense Advanced Research Projects Agency Antibody Technology Program Phase II: Characterization of an Anti-BclA Antibody Produced by Illumina, Inc.
Abstract
The Defense Advanced Research Projects Agency (DARPA; Arlington, VA) Antibody Technology Program (ATP) focused on the development of technologies that enhance the thermal stability and binding affinity of a given antibody. The U.S. Army Edgewood Chemical Biological Center (ECBC; now known as U.S. Army Combat Capabilities Development Command Chemical Biological Center; Aberdeen Proving Ground, MD) functioned as an independent testing laboratory to provide technical support on immune reagents and assist in defining the government-supplied antibody-antigen pairs. Project goals were to (1) implement standardized methods for characterizing antibodies developed at ECBC with de novo thermal and binding properties of select reagents for use by DARPA-funded investigators, and (2) use those methods to validate changes in antibody thermal stability and binding affinities achieved by DARPA investigators. The antibody chosen for this project was BA21, which detects the Bacillus collagen-like protein of anthracis (BclA). The focus was evaluation of the BA21 antibody supplied by Illumina, Inc. for affinity and stability enhancements. Results of this study include standardized parametric data on antibody properties and performance that will contribute to improvements for future detection and diagnostic platforms.
Document Details
- Document Type
- Technical Report
- Publication Date
- Dec 01, 2021
- Accession Number
- AD1155098
Entities
People
- Alena M. Calm
- Candice Warner
- Darrel Menking
- Heather Welsh
- James Carney
- Melody Zacharko
- Patricia E. Buckley
- Roy Thompson
Organizations
- United States Army Soldier Systems Center